635 related articles for article (PubMed ID: 32820253)
21. The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth.
Ramamurthy VP; Ramalingam S; Gediya LK; Njar VCO
FEBS J; 2018 Mar; 285(6):1051-1063. PubMed ID: 29323792
[TBL] [Abstract][Full Text] [Related]
22. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
26. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
Vellky JE; McSweeney ST; Ricke EA; Ricke WA
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
28. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
29. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
[No Abstract] [Full Text] [Related]
30. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
[TBL] [Abstract][Full Text] [Related]
31. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
32. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
[TBL] [Abstract][Full Text] [Related]
33. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.
Ho Y; Dehm SM
Endocrinology; 2017 Jun; 158(6):1533-1542. PubMed ID: 28368512
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
Shao C; Yu B; Liu Y
Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
[TBL] [Abstract][Full Text] [Related]
36. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract][Full Text] [Related]
37. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
Cato L; de Tribolet-Hardy J; Lee I; Rottenberg JT; Coleman I; Melchers D; Houtman R; Xiao T; Li W; Uo T; Sun S; Kuznik NC; Göppert B; Ozgun F; van Royen ME; Houtsmuller AB; Vadhi R; Rao PK; Li L; Balk SP; Den RB; Trock BJ; Karnes RJ; Jenkins RB; Klein EA; Davicioni E; Gruhl FJ; Long HW; Liu XS; Cato ACB; Lack NA; Nelson PS; Plymate SR; Groner AC; Brown M
Cancer Cell; 2019 Mar; 35(3):401-413.e6. PubMed ID: 30773341
[TBL] [Abstract][Full Text] [Related]
38. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
39. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
[TBL] [Abstract][Full Text] [Related]
40. PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.
Wang L; Song G; Zhang X; Feng T; Pan J; Chen W; Yang M; Bai X; Pang Y; Yu J; Han J; Han B
Cancer Res; 2017 Nov; 77(21):5755-5768. PubMed ID: 28819028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]